An ATR inhibitor blocks a checkpoint that helps cells survive stress while copying DNA. Combining it with a DNA-damaging payload on one antibody is being tested in early research.
CLIO-8221 carries exatecan and berzosertib, pairing TOP1-mediated damage with ATR checkpoint inhibition. The primary trial-design abstract describes preclinical activity and the planned assessment of safety, dosing and activity in people. The direct registry records a phase 1/2 trial. These sources establish the construct and its evaluation, not comparative benefit or a validated biomarker for choosing it after TOP1 treatment.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/